{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T01:48:20Z","timestamp":1792806500494,"version":"4.5.0"},"reference-count":22,"publisher":"American Medical Association (AMA)","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Netw Open"],"abstract":"\n Importance<\/jats:title>\n Trends in the incidence of de novo stage IV breast cancer in the general population and in the percentage with stage IV disease remain underreported.<\/jats:p>\n <\/jats:sec>\n \n Objectives<\/jats:title>\n To evaluate the incidence, percentage, and survival of people with de novo stage IV breast cancer diagnosed from 2010 through 2021.<\/jats:p>\n <\/jats:sec>\n \n Design, Setting, and Participants<\/jats:title>\n This population-based cohort study used data from the Surveillance, Epidemiology, and End Results program to identify all individuals diagnosed with de novo invasive breast cancer between January 1, 2010, and December 31, 2021. No exclusion criteria were applied. Data analyses were conducted from January 2024 to June 2025.<\/jats:p>\n <\/jats:sec>\n \n Main Outcomes and Measures<\/jats:title>\n Age-adjusted incidence rates of breast cancer and annual percentage changes (APC) from 2010 through 2021 were calculated. Among the diagnosed breast cancers, the yearly percentage of stage IV disease was also calculated. Changes in overall survival (OS) were evaluated for patients with stage IV breast cancer using multivariable Cox proportional hazards regression models stratified by tumor subtype.<\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n \n Of 761\u202f471 breast cancer diagnoses (median [IQR] age at diagnosis, 60 [50-70] years; 99.2% female), 43\u202f934 (5.8%) were stage IV. Stage IV incidence increased from 9.5 (95% CI, 9.2-9.9) cases per 100\u202f000 females in 2010 to 11.2 (95% CI, 10.9-11.6) cases per 100\u202f000 females in 2021, an APC of 1.2% (95% CI, 0.8%-1.6%). The incidence of stages I to III disease also increased, from 163.0 (95% CI, 161.6-164.4) cases per 100\u202f000 females in 2010 to 177.4 (95% CI, 176.1-178.8) cases per 100\u202f000 females in 2021. Stage IV incidence increased across all tumor subtypes, with an APC of 2.0% (95% CI, 1.5%-2.6%) for hormone receptor (HR)\u2013positive\/\n ERBB2<\/jats:italic>\n -negative, 1.6% (95% CI, 0.2%-2.9%) for HR-positive\/\n ERBB2<\/jats:italic>\n -positive, 1.3% (95% CI, \u22120.1%-2.7%) for HR-negative\/\n ERBB2<\/jats:italic>\n -positive, and 2.7% (95% CI, 1.4%-4%) for triple-negative disease. Stage IV incidence increased statistically significantly across all age groups and numerically across all racial groups. Among males, there was a statistically significant increase in stage IV incidence, with an APC of 3.7% (95% CI, 1.0%-6.5%). The percentage of stage IV diagnoses increased statistically significantly from 2010 through 2021 in each tumor subtype: 4.2% to 4.4% for HR-positive\/\n ERBB2<\/jats:italic>\n -negative, 7.5% to 9.1% for HR-positive\/\n ERBB2<\/jats:italic>\n -positive, 9.3% to 10.4% for HR-negative\/\n ERBB2<\/jats:italic>\n -positive disease, and 6.1% to 7.6% for triple-negative breast cancer. For each successive year, OS among patients diagnosed with stage IV improved, with adjusted hazard ratios of 0.99 (95% CI, 0.98-0.99) for HR-positive\/\n ERBB2<\/jats:italic>\n -negative, 0.97 (95% CI, 0.95-0.99) for HR-positive\/\n ERBB2<\/jats:italic>\n -positive, and 0.97 (95% CI, 0.94-0.99) for HR-negative\/\n ERBB2<\/jats:italic>\n -positive; changes for triple-negative breast cancer were not statistically significant (AHR, 0.99 [95% CI, 0.97-1.01];\n P<\/jats:italic>\n \u2009=\u2009.33).\n <\/jats:p>\n <\/jats:sec>\n \n Conclusions and Relevance<\/jats:title>\n In this cohort study of individuals with stage IV breast cancer, incidence increased significantly overall, across ages, and for both sexes from 2010 through 2021. The percentage of individuals with stage IV vs stages I to III diagnoses also increased. Although OS improved, research is warranted to determine factors contributing to increased incidence, including potential changes in natural history of breast cancer, disease screening, and incidence and mortality of other conditions.<\/jats:p>\n <\/jats:sec>","DOI":"10.1001\/jamanetworkopen.2026.12042","type":"journal-article","created":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T15:00:20Z","timestamp":1778598020000},"page":"e2612042","source":"Crossref","is-referenced-by-count":6,"title":["Stage IV Breast Cancer Incidence and Survival, 2010-2021"],"prefix":"10.1001","volume":"9","author":[{"given":"Jorge","family":"Avila","sequence":"first","affiliation":[{"name":"Department of Oncology, Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julieta","family":"Leone","sequence":"additional","affiliation":[{"name":"Grupo Oncol\u00f3gico Cooperativo Del Sur (GOCS), Neuqu\u00e9n, Argentina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nabihah","family":"Tayob","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts"},{"name":"Harvard Medical School, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meredith M.","family":"Regan","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts"},{"name":"Harvard Medical School, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlos T.","family":"Vallejo","sequence":"additional","affiliation":[{"name":"Grupo Oncol\u00f3gico Cooperativo Del Sur (GOCS), Neuqu\u00e9n, Argentina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael J.","family":"Hassett","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts"},{"name":"Harvard Medical School, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nancy U.","family":"Lin","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts"},{"name":"Harvard Medical School, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara M.","family":"Tolaney","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts"},{"name":"Harvard Medical School, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9 P.","family":"Leone","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts"},{"name":"Harvard Medical School, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","published-online":{"date-parts":[[2026,5,12]]},"reference":[{"issue":"6","key":"zoi260366r1","doi-asserted-by":"publisher","first-page":"809","DOI":"10.1158\/1055-9965.EPI-16-0889","article-title":"Estimation of the number of women living with metastatic breast cancer in the United States.","volume":"26","author":"Mariotto","year":"2017","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"issue":"17","key":"zoi260366r2","doi-asserted-by":"publisher","first-page":"4287","DOI":"10.3390\/cancers13174287","article-title":"Breast cancer-epidemiology, risk factors, classification, prognostic markers, and current treatment strategies\u2014an updated review.","volume":"13","author":"Lukasiewicz","year":"2021","journal-title":"Cancers (Basel)"},{"issue":"6","key":"zoi260366r3","first-page":"477","article-title":"Breast cancer statistics 2024.","volume":"74","author":"Giaquinto","year":"2024","journal-title":"CA Cancer J Clin"},{"issue":"8","key":"zoi260366r4","doi-asserted-by":"publisher","first-page":"800","DOI":"10.1001\/jama.2013.776","article-title":"Incidence of breast cancer with distant involvement among women in the United States, 1976 to 2009.","volume":"309","author":"Johnson","year":"2013","journal-title":"JAMA"},{"issue":"1","key":"zoi260366r5","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1001\/jamaoncol.2023.4837","article-title":"Global stage distribution of breast cancer at diagnosis: a systematic review and meta-analysis.","volume":"10","author":"Benitez Fuentes","year":"2024","journal-title":"JAMA Oncol"},{"issue":"3","key":"zoi260366r6","doi-asserted-by":"publisher","DOI":"10.1093\/jncics\/pkz040","article-title":"Incidence and survival among young women with stage I-III breast cancer: SEER 2000-2015.","volume":"3","author":"Thomas","year":"2019","journal-title":"J Natl Cancer Inst Cancer Spectr"},{"issue":"1","key":"zoi260366r8","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1002\/sim.4780040112","article-title":"A Wilcoxon-type test for trend.","volume":"4","author":"Cuzick","year":"1985","journal-title":"Stat Med"},{"issue":"21","key":"zoi260366r9","doi-asserted-by":"publisher","first-page":"1998","DOI":"10.1056\/NEJMoa1206809","article-title":"Effect of three decades of screening mammography on breast-cancer incidence.","volume":"367","author":"Bleyer","year":"2012","journal-title":"N Engl J Med"},{"issue":"15","key":"zoi260366r10","doi-asserted-by":"publisher","first-page":"1685","DOI":"10.1001\/jama.2009.1498","article-title":"Rethinking screening for breast cancer and prostate cancer.","volume":"302","author":"Esserman","year":"2009","journal-title":"JAMA"},{"issue":"23","key":"zoi260366r11","doi-asserted-by":"publisher","first-page":"2286","DOI":"10.1056\/NEJMsr1613680","article-title":"Are small breast cancers good because they are small or small because they are good?","volume":"376","author":"Lannin","year":"2017","journal-title":"N Engl J Med"},{"issue":"24","key":"zoi260366r12","article-title":"Abstract P3-06-14: Increase in the proportion of stage IV breast cancer amongst young women with newly diagnosed breast cancer, report from the national cancer data base, 1998-2009.","volume":"73","author":"Yao","year":"2013","journal-title":"Cancer Res"},{"issue":"22","key":"zoi260366r13","doi-asserted-by":"publisher","first-page":"1918","DOI":"10.1001\/jama.2024.5534","article-title":"Screening for breast cancer: US Preventive Services Task Force recommendation statement.","volume":"331","author":"Nicholson","year":"2024","journal-title":"JAMA"},{"issue":"3","key":"zoi260366r14","first-page":"34","article-title":"Disparities in breast cancer stage at diagnosis: importance of race, poverty, and age.","volume":"10","author":"Williams","year":"2017","journal-title":"J Health Dispar Res Pract"},{"issue":"11","key":"zoi260366r15","doi-asserted-by":"publisher","first-page":"1666","DOI":"10.1158\/1055-9965.EPI-15-0293","article-title":"Racial disparities in breast cancer diagnosis and treatment by hormone receptor and HER2 status.","volume":"24","author":"Chen","year":"2015","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"issue":"4","key":"zoi260366r16","doi-asserted-by":"publisher","first-page":"706","DOI":"10.1007\/s40615-016-0274-4","article-title":"Regional variation in disparities in breast cancer specific mortality due to race\/ethnicity, socioeconomic status, and urbanization.","volume":"4","author":"Parise","year":"2017","journal-title":"J Racial Ethn Health Disparities"},{"issue":"1","key":"zoi260366r17","doi-asserted-by":"publisher","first-page":"9067","DOI":"10.1038\/s41598-023-36139-8","article-title":"Association between marital status and all-cause mortality of patients with metastatic breast cancer: a population-based study.","volume":"13","author":"Zhu","year":"2023","journal-title":"Sci Rep"},{"issue":"3","key":"zoi260366r18","doi-asserted-by":"publisher","first-page":"778","DOI":"10.1016\/j.ygyno.2021.06.008","article-title":"The impact of marital status on stage at diagnosis and survival of female patients with breast and gynecologic cancers: a meta-analysis.","volume":"162","author":"Yuan","year":"2021","journal-title":"Gynecol Oncol"},{"issue":"6","key":"zoi260366r19","doi-asserted-by":"publisher","first-page":"1559","DOI":"10.1007\/s00432-020-03184-z","article-title":"Improved survival in metastatic breast cancer: results from a 20-year study involving 1033 women treated at a single comprehensive cancer center.","volume":"146","author":"Welt","year":"2020","journal-title":"J Cancer Res Clin Oncol"},{"issue":"1","key":"zoi260366r20","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1002\/cncr.11859","article-title":"Is breast cancer survival improving?","volume":"100","author":"Giordano","year":"2004","journal-title":"Cancer"},{"issue":"6","key":"zoi260366r21","doi-asserted-by":"publisher","first-page":"394","DOI":"10.3322\/caac.21492","article-title":"Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries.","volume":"68","author":"Bray","year":"2018","journal-title":"CA Cancer J Clin"},{"issue":"9","key":"zoi260366r22","doi-asserted-by":"publisher","first-page":"2289","DOI":"10.1002\/ijc.33417","article-title":"Comprehensive trends in incidence, treatment, survival and mortality of first primary invasive breast cancer stratified by age, stage and receptor subtype in the Netherlands between 1989 and 2017.","volume":"148","author":"van der Meer","year":"2021","journal-title":"Int J Cancer"},{"key":"zoi260366r7","unstructured":"Overview of the SEER Program. National Cancer Institute Survellance, Epidemiology and End Results Program. Accessed March 27, 2026. https:\/\/seer.cancer.gov\/about\/overview.html"}],"container-title":["JAMA Network Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/articlepdf\/2848858\/avila_2026_oi_260366_1784037029.76688.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T15:00:43Z","timestamp":1784127643000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/fullarticle\/2848858"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,12]]},"references-count":22,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,5,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamanetworkopen.2026.12042","relation":{},"ISSN":["2574-3805"],"issn-type":[{"value":"2574-3805","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,12]]}}}